Anifrolumab PK study for Systemic Lupus Erythematosus (SLE)

Study identifier:D3468C00002

ClinicalTrials.gov identifier:NCT05001698

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase I, Open-label, Single-Arm, Multiple-Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Anifrolumab in Chinese Participants with Systemic Lupus Erythematosus (SLE)

Medical condition

Systemic Lupus Erythematosus

Phase

Phase 1

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

15

Study type

Interventional

Age

18 Years - 60 Years

Date

Study Start Date: 27 Jul 2021
Primary Completion Date: 02 Jun 2022
Study Completion Date: 02 Jun 2022

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 May 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria